source
- FDA issues complete response letter, rejecting Summit Therapeutics' ivonescimab for EGFR-mutated lung cancerThe U.S. Food and Drug Administration sent a complete response letter to Summit Therapeutics, declining to approve its bispecific antibody ivonescimab for patients with previously treated EGFR‑muta…
- Takeda narcolepsy pill receives DEA clearance as Oura-Lilly deal raises conflict concerns and Pfizer exits Canadian Premarin marketTakeda announced that its experimental narcolepsy medication has been cleared by the U.S. Drug Enforcement Administration, marking the first regulatory nod for a therapy aimed at treating excessive…STAT · 2d agoRegulatoryPositive